Repros Therapeutics Inc.
RPRX
RPRX was delisted on the 31st of January, 2018.
29 hedge funds and large institutions have $2.51M invested in Repros Therapeutics Inc. in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 13 reducing their positions, and 6 closing their positions.
7,333% more call options, than puts
Call options by funds: $223K | Put options by funds: $3K
12% less funds holding
Funds holding: 33 → 29 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
67% less capital invested
Capital invested by funds: $7.64M → $2.51M (-$5.13M)
77% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$166K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$69.3K |
| 3 |
AIA
Allegis Investment Advisors
Idaho Falls,
Idaho
|
+$23.7K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$7.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$935K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$137K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$69.4K |
| 4 |
BlackRock
New York
|
-$62.6K |
| 5 |
GAI
General American Investors
New York
|
-$50.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIM
26
Acrospire Investment Management
Chicago,
Illinois
| – | -$30K | -24,881 | Closed |
|
27
Barclays
London,
United Kingdom
| – | -$2.85K | -3,931 | -95% |
|
28
Simplex Trading
Chicago,
Illinois
| – | -$2.17K | -2,985 | Closed |
|
29
UBS Group
Zurich,
Switzerland
| – | -$878 | -1,209 | -92% |
|
30
Citigroup
New York
| – | -$1K | -985 | Closed |
|
RPRX Hedge Fund Activity: Q2 2017 in Review
29 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics Inc. (RPRX) for Q2 2017, worth a combined $2.51M — down 67% from $7.64M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of RPRX and 2 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $166K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $935K sold.
- 29 institutional investors held Repros Therapeutics Inc. (RPRX) as of Q2 2017, down from 33 in Q1 2017.
- Funds reported $2.51M of Repros Therapeutics Inc. stock for Q2 2017, down 67% quarter-over-quarter.
- 2 funds opened new Repros Therapeutics Inc. positions in Q2 2017 and 6 closed out, a net change of -4 holders.
- The largest Repros Therapeutics Inc. buyer in Q2 2017 was Renaissance Technologies, an estimated $166K added.
- The largest Repros Therapeutics Inc. seller in Q2 2017 was Sphera Funds Management, an estimated $935K sold.
Based on aggregated 13F filings for Q2 2017.